Total and regional bone mineral content in women treated with GnRH agonists.
Changes in bone mineral content induced by GnRH agonists were investigated by measuring total body bone mineral content (TBBM) and regional bone mineral content (BMC) (arms, legs, trunk, pelvis) and densities with dual energy X-ray absorptiometry in 25 premenopausal women before and after a 6-month treatment with gonadotropin-releasing hormone (GnRH) agonists. Biological markers of bone remodeling, estrogens, luteinizing hormone, and follicle-stimulating hormone were also measured. Weight and body mass index increased significantly after treatment (P < 0.05), and TBBM, corrected for weight (TBBM/W), decreased (P < 0.001). The changes in BMC that we observed ranged from +2.5% to -6.9%. The greatest decrease in regional BMC occurred in the trunk (4.4%, P < 0.001), with TBBM decreasing by 2.1% (P < 0.001). No significant changes were observed in the limbs. Tartrate-resistant acid phosphatase (TRAP) increased significantly after treatment (P < 0.001) and a significant negative correlation between TRAP and TBBM (P < 0.001) and between TRAP and estradiol (P < 0.001) were observed before treatment. The lack of changes observed in the BMC of the limbs indicate that GnRH agonists cause a preferential loss of BMC in trunk osseous structures, a situation similar to that of the first years of menopause.
Department of Medicine, Principe de Asturias, University Hospital, Alcalá de Henares University, Madrid, Spain.
H
H
Rico
F
F
Arnanz
M
M
Revilla
S
S
Perera
M
M
Iritia
L F
LF
Villa
I
I
Arribas
D015502:Absorptiometry, Photon; D000135:Acid Phosphatase / Q000097:blood; D000328:Adult; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects*; D016723:Bone Remodeling; D004967:Estrogens / Q000097:blood; D005260:Female; D006801:Humans; D017329:Triptorelin Pamoate / Q000494:pharmacology*
D004967:Estrogens; D017329:Triptorelin Pamoate; D000135:Acid Phosphatase